Investors ditch Biota on BARDA laninamivir 'stop-work' order
This article was originally published in Scrip
Executive Summary
Shares of Biota Pharmaceuticals spiraled down more than 37% on 29 April the Biomedical Advanced Research and Development Authority (BARDA) issued a stop-work order notifying the company to discontinue work on laninamivir octanoate, pending a decision about the outcome of a recently completed in-process review (IPR) of the firm's contract.